Colony-Stimulating Factors

Verified · Oct 2026

Prototype: filgrastim

Colony-Stimulating Factors are a class of medications used for prevention/treatment of chemotherapy-induced neutropenia.

G-CSF agents — they rebuild the infection-fighting white cells that chemotherapy wipes out.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Neutropenia — the dangerous side effect of chemotherapy

Chemotherapy kills fast-dividing cells — including the marrow cells that make neutrophils, the white cells that fight bacterial infection. The resulting neutropenia leaves patients dangerously vulnerable: a fever in a neutropenic patient (febrile neutropenia) is a medical emergency because they can’t mount a normal defense.

Colony-stimulating factors are lab-made versions of the body’s own signal (G-CSF — filgrastim/pegfilgrastim; GM-CSF — sargramostim) that tell the marrow to ramp up neutrophil production, shortening the neutropenic window and reducing infection risk.

Loading diagram…

G-CSF drives the marrow to rebuild neutrophils faster after chemotherapy.

02 Bone pain, timing, and the rare emergencies

The hallmark side effect follows from the mechanism: a stimulated marrow causes bone pain (often back pain or pain in the limbs) — the most common adverse effect with pegfilgrastim (31% vs 26% on placebo; 11% vs 6% with filgrastim) — usually manageable with acetaminophen or an NSAID. Pegfilgrastim is the long-acting form given once per chemo cycle; filgrastim is given daily.

Two rare but serious effects to know: splenic rupture (the spleen can enlarge and rupture — report sudden left-upper-quadrant or shoulder-tip pain) and acute respiratory distress syndrome (ARDS). Timing matters too: filgrastim is not given in the 24 hours before chemotherapy (first dose at least 24 hours after), pegfilgrastim not from 14 days before to 24 hours after it, and sargramostim not within 24 hours before or after chemotherapy or radiotherapy, because stimulating the marrow while cytotoxic drug is present would expose the new dividing cells to it.

Drug names

Generic Brand

filgrastim Neupogen

pegfilgrastim Neulasta

sargramostim (GM-CSF) Leukine

Indications

Prevention/treatment of chemotherapy-induced neutropenia (reduce febrile neutropenia)
Severe chronic/congenital neutropenia
Mobilization of stem cells and post–bone-marrow-transplant recovery (filgrastim, sargramostim — pegfilgrastim is not indicated for mobilization)
Acute radiation syndrome (hematopoietic) — filgrastim, pegfilgrastim, and sargramostim are labeled to increase survival after exposure to marrow-suppressing doses of radiation

Mechanism of action

Recombinant granulocyte colony-stimulating factor (filgrastim/pegfilgrastim) — and GM-CSF (sargramostim) — bind marrow progenitor receptors, stimulating proliferation, differentiation, and release of neutrophils.

In plain terms

They tell the bone marrow to pump out more infection-fighting white blood cells after chemo.

Therapeutic effects — what you'll see working

Success is a rising absolute neutrophil count (ANC) and fewer/shorter febrile-neutropenia episodes. Time doses around — not during — chemotherapy.

↑ Neutrophil count (ANC) Fewer infections

↑ Neutrophil count (ANC): Stimulates the marrow to raise the ANC, shortening the period of dangerous neutropenia after chemotherapy.
Fewer infections: A faster neutrophil recovery reduces febrile neutropenia and infection-related complications and hospitalizations — in one trial of patients 65 and older, starting pegfilgrastim with the first chemotherapy cycle (rather than after a problem appeared) cut neutropenia-related hospitalizations by about half.

Adverse effects

The hallmark effect (bone pain) reflects marrow stimulation; the serious effects (splenic rupture, ARDS) are rare but must be recognized.

Common Expected

Bone/musculoskeletal pain, fever, headache, injection-site reactions.

Bone pain (about 11% with filgrastim and 31% with pegfilgrastim in trials) reflects marrow stimulation and is usually managed with acetaminophen or NSAIDs (loratadine is not recommended by ASCO).

Serious Report immediately

Splenic rupture (LUQ/shoulder pain); acute respiratory distress syndrome; serious allergic reactions; sickle cell crisis (in SCD); glomerulonephritis; capillary leak syndrome; aortitis/large-vessel arteritis; alveolar hemorrhage; very high white counts; MDS/AML.

Splenic rupture is rare but life-threatening — sudden left-upper-quadrant or left shoulder pain warrants urgent evaluation. ARDS can present with fever, lung infiltrates, or respiratory distress. Anaphylaxis and, in sickle cell disease, precipitated crises can occur. Capillary leak syndrome (low blood pressure, low albumin, edema, hemoconcentration) can be life-threatening if treatment is delayed — monitor closely. Aortitis/arteritis can appear as early as the first week, with fever, abdominal or back pain, headache, neck pain, and raised inflammatory markers. Glomerulonephritis shows as azotemia, hematuria, and proteinuria and usually resolves with dose reduction or stopping. Alveolar hemorrhage with hemoptysis has been reported in healthy stem-cell donors given filgrastim. White counts of 100,000/mm³ or more have occurred — monitor the CBC (filgrastim is stopped once the ANC passes 10,000/mm³ after the chemotherapy nadir). MDS and AML have been linked to G-CSF use with chemotherapy or radiotherapy in breast and lung cancer.

Contraindications

The key rules are timing around chemotherapy and hypersensitivity.

Dosing too close to cytotoxic chemotherapy (filgrastim: not within 24 h before, start ≥ 24 h after; pegfilgrastim: not from 14 days before to 24 h after; sargramostim: not within 24 h before or after chemotherapy or radiotherapy) use caution

Labeled timing rules: stimulating the marrow while chemo is present exposes newly dividing cells to the cytotoxic drug.

History of serious allergic reaction to a G-CSF (filgrastim/pegfilgrastim) or, for sargramostim, to GM-CSF or yeast-derived products

Labeled contraindication — serious allergic reactions, including anaphylaxis, have occurred.

Neulasta on-body injector — reactions to acrylic adhesives use caution

The on-body injector uses an acrylic adhesive, so a patient who reacts to acrylic adhesives may have a significant reaction.

Labs & levels

Test Therapeutic / normal Toxic / critical

Absolute neutrophil count (ANC) Monitor with the CBC to track neutrophil recovery Normal range ≥ 1,500/µL (adults typically ~2,500–7,000; neutropenia below 1,500, severe below 500) —

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Administration & monitoring

Monitor the CBC/absolute neutrophil count; time doses by product — filgrastim not within 24 h before chemo (start ≥ 24 h after), pegfilgrastim not from 14 days before to 24 h after, sargramostim not within 24 h before or after.

Why: The ANC guides therapy, and correct timing protects the new cells from cytotoxic drug.

Treat bone pain with acetaminophen or an NSAID (if appropriate) and explain it is an expected effect.

Why: Bone pain is the most common effect with pegfilgrastim and reflects marrow stimulation.

Patient teaching

Report sudden left-upper-abdomen or left-shoulder pain or new shortness of breath.

Why: These flag the rare emergencies — splenic rupture and ARDS — that require urgent care.

With the Neulasta on-body injector, call the care team right away if the device may not have delivered the full dose.

Why: Missed or partial doses from device failure raise the risk of neutropenia, febrile neutropenia, and infection; the team decides whether a replacement dose is needed.

Common questions

What are Colony-Stimulating Factors used for?

Colony-Stimulating Factors are used for prevention/treatment of chemotherapy-induced neutropenia, severe chronic/congenital neutropenia, mobilization of stem cells and post–bone-marrow-transplant recovery, and acute radiation syndrome.

How do Colony-Stimulating Factors work?

They tell the bone marrow to pump out more infection-fighting white blood cells after chemo.

What are the serious side effects of Colony-Stimulating Factors?

Watch for splenic rupture (LUQ/shoulder pain); acute respiratory distress syndrome; serious allergic reactions; sickle cell crisis (in SCD); glomerulonephritis; capillary leak syndrome; aortitis/large-vessel arteritis; alveolar hemorrhage; very high white counts; MDS/AML.

What labs should be monitored with Colony-Stimulating Factors?

Monitor absolute neutrophil count (ANC).

Conditions treated

Leukemias

Patho · Hematologic

Given to shorten the neutropenic window rather than to treat an established infection, and the indication is a risk threshold, not a count: "Patients with a ≥ 20% risk of febrile neutropenia may benefit from using colony-stimulating factors." Where neutropenia is established, G-CSF "is the treatment mainstay," working best where the defect is in myelopoiesis, with a goal of raising the ANC above 1,000 cells/μL. The disorder-side adverse effect nurses meet constantly is G-CSF-associated bone pain, which patients need warned about in advance so they do not read it as disease progression.

Lymphomas